2025 Net Revenue of $295-300M, EBITDA margin of 30%+ Expansion of VALTOCO (diazepam nasal spray) Patent Portfolio, Extending Market Exclusivity with multiple issuances through 2032 Accelerated Uptake with VALTOCO FDA Label Expansion Approval Including 2 to 5 years of Age San Diego, CA – January 12, 2026 – Neurelis, Inc., the innovator behind VALTOCO® […] The post NEURELIS PROVIDES BUSINESS UPDATE HIGHLIGHTING TRANSFORMATIONAL 2025 RESULTS first appeared on Neurelis, Inc. .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules